HC Wainwright Issues Pessimistic Forecast for YMAB Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Analysts at HC Wainwright cut their Q2 2025 earnings per share estimates for shares of Y-mAbs Therapeutics in a research note issued on Monday, May 19th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.23) per share for the quarter, down from their previous estimate of ($0.22). HC Wainwright currently has a "Buy" rating and a $11.00 target price on the stock. The consensus estimate for Y-mAbs Therapeutics' current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Y-mAbs Therapeutics' Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.23) EPS.

A number of other brokerages have also recently issued reports on YMAB. Truist Financial lowered their price target on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Morgan Stanley decreased their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research note on Wednesday, March 5th. Wedbush reiterated an "outperform" rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. Bank of America cut Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a research report on Tuesday, April 22nd. Finally, Oppenheimer reduced their price objective on Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a research report on Wednesday, May 14th. Two analysts have rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Y-mAbs Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.60.

Y-mAbs Therapeutics Stock Up 4.6%

Shares of YMAB stock traded up $0.19 during mid-day trading on Wednesday, reaching $4.32. 324,293 shares of the company's stock traded hands, compared to its average volume of 312,434. The company's 50-day moving average price is $4.41 and its 200-day moving average price is $6.62. The company has a market cap of $195.63 million, a P/E ratio of -8.00 and a beta of 0.53. Y-mAbs Therapeutics has a 12 month low of $3.55 and a 12 month high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.10. The company had revenue of $20.90 million for the quarter, compared to analysts' expectations of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%.

Institutional Trading of Y-mAbs Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of YMAB. Brooklyn Investment Group lifted its holdings in shares of Y-mAbs Therapeutics by 4,563.8% during the first quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock valued at $26,000 after purchasing an additional 5,796 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Y-mAbs Therapeutics during the 4th quarter valued at about $46,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Y-mAbs Therapeutics during the 1st quarter valued at about $49,000. Corton Capital Inc. purchased a new stake in shares of Y-mAbs Therapeutics during the 1st quarter valued at about $55,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Y-mAbs Therapeutics in the first quarter worth approximately $56,000. Institutional investors own 70.85% of the company's stock.

Insider Activity

In related news, insider Thomas Gad sold 10,810 shares of the company's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares of the company's stock, valued at approximately $1,060,230.83. This represents a 5.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 22.50% of the company's stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.